Novel Risk Factors for Acute Coronary Syndromes and Emerging Therapies
Overview
Authors
Affiliations
Acute coronary syndromes represent not merely disrupted atherosclerotic plaques or luminal stenoses but rather a complex clinical syndrome. The traditional conception of pathogenesis and management of ACS has been challenged by numerous recent landmark ACS trials. Current prognostication models lack clinical precision and can be challenging to the clinicians in tailoring management strategies for individual patients. In this review we summarise the emerging evidence of novel risk factors (plaque phenotype, coronary blood flow, endothelial dysfunction, microvascular dysfunction, and inflammation) in predicting future events and outcomes in ACS population. As the search for miracle cure for ischaemic heart disease continues, one is hopeful that emerging therapeutic approaches targeting these novel risk factors will improve long-term outcomes of ACS.
Evaluation of Growth Differentiation Factor-15 in Patients with or without Coronary Artery Disease.
Hassanzadeh Daloee S, Nakhaei N, Hassanzadeh Daloee M, Mahmoodi M, Barzegar-Amini M Acta Biomed. 2021; 92(2):e2021051.
PMID: 33988174 PMC: 8182609. DOI: 10.23750/abm.v92i2.9267.
Therapeutic Efficacy and Safety of Safflower Injection in the Treatment of Acute Coronary Syndrome.
Lu Q, Xu J, Li Q, Wu W, Wu Y, Xie J Evid Based Complement Alternat Med. 2021; 2021:6617772.
PMID: 33790976 PMC: 7994092. DOI: 10.1155/2021/6617772.
Virtanen M, Vahtera J, Singh-Manoux A, Elovainio M, Ferrie J, Kivimaki M Int J Cardiol. 2018; 269:7-12.
PMID: 30005835 PMC: 6152587. DOI: 10.1016/j.ijcard.2018.07.005.
Kouvari M, Chrysohoou C, Aggelopoulos P, Tsiamis E, Tsioufis K, Pitsavos C Eur J Clin Nutr. 2017; .
PMID: 28832572 DOI: 10.1038/ejcn.2017.122.